Tags

Type your tag names separated by a space and hit enter

Resazurin microtitre plate assay and Sensititre® MycoTB for detection of Mycobacterium tuberculosis resistance in a high tuberculosis resistance setting.
Afr J Lab Med 2019; 8(1):840AJ

Abstract

Background

Rapid diagnosis of drug-resistant Mycobacterium tuberculosis is a challenge in low-income countries. Phenotypic drug susceptibility testing using Sensititre® MycoTB assay and the resazurin microtitre plate assay (REMA) are relatively new innovative methods to determine drug susceptibility.

Objectives

This study aimed to determine the performance of the Sensititre and REMA for M. tuberculosis drug susceptibility testing in a high-volume tuberculosis reference laboratory.

Methods

A laboratory-based study was performed at the Inkosi Albert Luthuli Central Hospital Tuberculosis Laboratory from January 2014 to June 2015. The Sensititre® MycoTB plate and REMA were compared to the gold standard agar proportion method (APM) using 134 stored isolates.

Results

Agreement between the Sensititre® MycoTB plate and APM was observed with 98% sensitivity, 82% specificity, 94% positive and 93% negative predictive values of the Sensititre® MycoTB assay for the detection of rifampicin resistance and 97%, 96%, 99% and 88% for isoniazid resistance. Good categorical agreement between the REMA and the APM was observed among isolates with 89% sensitivity, 68% specificity, 89% positive and 68% negative predictive value for the detection of rifampicin resistance and 95%, 96%, 99% and 81% for isoniazid resistance. Results for the second-line drugs showed elevated minimum inhibitory concentrations for multidrug-resistant and extensively drug-resistant tuberculosis isolates.

Conclusion

The REMA and Sensititre® MycoTB plate are attractive alternatives to the gold standard APM for the phenotypic detection of M. tuberculosis drug resistance.

Authors+Show Affiliations

Department of Medical Microbiology, National Health Laboratory Services, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa.Department of Medical Microbiology/Virology, National Health Laboratory Service, Durban, South Africa.Department of Medical Microbiology, National Health Laboratory Services, School of Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31956551

Citation

Jaglal, Prenika, et al. "Resazurin Microtitre Plate Assay and Sensititre® MycoTB for Detection of Mycobacterium Tuberculosis Resistance in a High Tuberculosis Resistance Setting." African Journal of Laboratory Medicine, vol. 8, no. 1, 2019, p. 840.
Jaglal P, Pillay M, Mlisana K. Resazurin microtitre plate assay and Sensititre® MycoTB for detection of Mycobacterium tuberculosis resistance in a high tuberculosis resistance setting. Afr J Lab Med. 2019;8(1):840.
Jaglal, P., Pillay, M., & Mlisana, K. (2019). Resazurin microtitre plate assay and Sensititre® MycoTB for detection of Mycobacterium tuberculosis resistance in a high tuberculosis resistance setting. African Journal of Laboratory Medicine, 8(1), p. 840. doi:10.4102/ajlm.v8i1.840.
Jaglal P, Pillay M, Mlisana K. Resazurin Microtitre Plate Assay and Sensititre® MycoTB for Detection of Mycobacterium Tuberculosis Resistance in a High Tuberculosis Resistance Setting. Afr J Lab Med. 2019;8(1):840. PubMed PMID: 31956551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resazurin microtitre plate assay and Sensititre® MycoTB for detection of Mycobacterium tuberculosis resistance in a high tuberculosis resistance setting. AU - Jaglal,Prenika, AU - Pillay,Melendhran, AU - Mlisana,Koleka, Y1 - 2019/12/13/ PY - 2018/05/30/received PY - 2019/03/13/accepted PY - 2020/1/21/entrez PY - 2020/1/21/pubmed PY - 2020/1/21/medline KW - Mycobacterium tuberculosis KW - Sensititre® MycoTB assay KW - agar proportion method KW - extensively drug-resistant tuberculosis KW - multidrug-resistant tuberculosis KW - resazurin microtitre plate assay SP - 840 EP - 840 JF - African journal of laboratory medicine JO - Afr J Lab Med VL - 8 IS - 1 N2 - Background: Rapid diagnosis of drug-resistant Mycobacterium tuberculosis is a challenge in low-income countries. Phenotypic drug susceptibility testing using Sensititre® MycoTB assay and the resazurin microtitre plate assay (REMA) are relatively new innovative methods to determine drug susceptibility. Objectives: This study aimed to determine the performance of the Sensititre and REMA for M. tuberculosis drug susceptibility testing in a high-volume tuberculosis reference laboratory. Methods: A laboratory-based study was performed at the Inkosi Albert Luthuli Central Hospital Tuberculosis Laboratory from January 2014 to June 2015. The Sensititre® MycoTB plate and REMA were compared to the gold standard agar proportion method (APM) using 134 stored isolates. Results: Agreement between the Sensititre® MycoTB plate and APM was observed with 98% sensitivity, 82% specificity, 94% positive and 93% negative predictive values of the Sensititre® MycoTB assay for the detection of rifampicin resistance and 97%, 96%, 99% and 88% for isoniazid resistance. Good categorical agreement between the REMA and the APM was observed among isolates with 89% sensitivity, 68% specificity, 89% positive and 68% negative predictive value for the detection of rifampicin resistance and 95%, 96%, 99% and 81% for isoniazid resistance. Results for the second-line drugs showed elevated minimum inhibitory concentrations for multidrug-resistant and extensively drug-resistant tuberculosis isolates. Conclusion: The REMA and Sensititre® MycoTB plate are attractive alternatives to the gold standard APM for the phenotypic detection of M. tuberculosis drug resistance. SN - 2225-2002 UR - https://www.unboundmedicine.com/medline/citation/31956551/Resazurin_microtitre_plate_assay_and_Sensititre®_MycoTB_for_detection_of_Mycobacterium_tuberculosis_resistance_in_a_high_tuberculosis_resistance_setting L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31956551/ DB - PRIME DP - Unbound Medicine ER -